Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- Products
-
- Duloxetine Delayed-Release Capsules
- Where it was sold
-
U.S. Nationwide
Nationwide
- Units affected
- 12,242 30-count bottles
- About this recall
- Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.